Although no differences were observed in plasma ChATactivity and protein concentration among ChEI-treated and untreated AD patients,ChAT activity and protein levels variance in plasma were higher among therivastigmine-treated group (ChAT protein: p = 0.005; ChAT activity: p = 0.0002).Moreover, AD patients homozygous for SNP rs1880676 A alleleexhibited higher levels of ChAT activity. The gene discussed is CHAT; the disease is Alzheimer disease.